GlassScriptPhysician profile
James L Carlisle
NPI 1851590079
$5,353.55
in general payments reported to CMS, 2019-2025
27 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $167 · 2021: $307 · 2022: $1,002 · 2023: $1,490 · 2024: $757 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900 · Travel and Lodging: $87.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900.00 |
| Travel and Lodging | $87.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,323.18 | 2019-2023 | |
| Foundation Fusion Solutions, LLC | $935.63 | 2024-2025 | |
| Nevro Corp. | $630.00 | 2021-2024 | Senza |
| Collegium Pharmaceutical, INC. | $329.23 | 2019-2024 | Xtampza |
| Sage Therapeutics, LLC | $286.21 | 2021-2023 | |
| Globus Medical, INC. | $242.43 | 2025 | Senza, Vyrsa V1 |
| Gilead Sciences, INC. | $240.85 | 2019-2022 | |
| Forte Bio-Pharma LLC | $239.07 | 2022-2024 | Prolate, Nalocet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.57 | 2019-2022 | |
| Mdd US Operations, LLC | $141.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $124.13 | 2022 | |
| Genentech, INC. | $109.91 | 2019 | |
| Abbott Laboratories | $91.95 | 2019-2021 | |
| Si-Bone, INC. | $71.93 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $62.30 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $52.10 | 2025 | Evoke |
| Horizon Therapeutics Plc | $48.57 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.52 | 2019 | |
| Biodelivery Sciences International, INC. | $30.97 | 2019-2021 | |
| Fidia Pharma USA INC. | $29.86 | 2019 | |
| Depuy Synthes Sales INC. | $21.77 | 2019 | |
| Avanos Medical | $21.64 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.53 | 2025 | |
| Nalu Medical, INC. | $18.87 | 2025 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $15.66 | 2019 | |
| Medtronic, INC. | $15.13 | 2024 | Intellis Adaptivestim |
| Epimed International, INC | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Carlisle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.